Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful faithfully but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. My first CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire interview which I came away with an inadequate impression of the company.

Irony of irony, the poor impression of mine of the company has grown steadily, although the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise and linked intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) and the first new drug application approval ($five million), and also royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and many therapies, it’s this individual treatments and a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple delivering presentations in addition to multiple publications.

Might all of it be smoke cigarettes and mirrors? That is a question I have been asking myself from the very start of my interest in this business. Judging by way of the multiples of thousands of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a classic battleground, or some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *